Dopamine neuronal loss contributes to memory and reward dysfunction in a model of Alzheimer's disease

Nature Communications

Volumn 8, Issue , 2017, Pages

  Nobili, Annalisa ^a,b   Latagliata, Emanuele Claudio ^a   Viscomi, Maria Teresa ^a,b   Cavallucci, Virve ^a,b,g   Cutuli, Debora ^a   Giacovazzo, Giacomo ^a,c   Krashia, Paraskevi ^a,d   Rizzo, Francesca Romana ^a,d   Marino, Ramona ^a,d   Federici, Mauro ^b   De Bartolo, Paola ^a   Aversa, Daniela ^a,e   Dell'Acqua, Maria Concetta ^a,d   Cordella, Alberto ^a,d   Sancandi, Marco ^f   Keller, Flavio ^b   Petrosini, Laura ^a,f   Puglisi Allegra, Stefano ^a,f   Mercuri, Nicola Biagio ^a,d   Coccurello, Roberto ^a,c   Berretta, Nicola ^a   D'Amelio, Marcello ^a,b   more..

^a IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^c CNR   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e GUGLIELMO MARCONI UNIVERSITY   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN; DOPAMINE; GLIAL FIBRILLARY ACIDIC PROTEIN; DOPA; SELEGILINE;

APOPTOSIS; BRAIN; GENE EXPRESSION; MEMORY; NERVOUS SYSTEM DISORDER; NEUROLOGY; NUTATION; ORGANIC NITROGEN COMPOUND; PROTEIN; RODENT; SYMPTOM;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL ACTIVATION; CELL LOSS; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DORSAL STRIATUM; DOWN REGULATION; GENE OVEREXPRESSION; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MEMORY DISORDER; MESENCEPHALON; MICROGLIA; MOTIVATION; MOUSE; NERVE CELL DEGENERATION; NERVE CELL PLASTICITY; NONHUMAN; NUCLEUS ACCUMBENS SHELL; REWARD; SUBSTANTIA NIGRA PARS COMPACTA; TG2576 MOUSE; VENTRAL TEGMENTUM; AMYLOID PLAQUE; ANIMAL; APOPTOSIS; CELL DEATH; COMPLICATION; DENDRITIC SPINE; DISEASE MODEL; DRUG EFFECT; FOOD; HIPPOCAMPUS; INFLAMMATION; MEMORY; METABOLISM; NERVE DEGENERATION; NUCLEUS ACCUMBENS; PATHOLOGY; PATHOPHYSIOLOGY; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; ANIMALS; APOPTOSIS; CELL DEATH; DENDRITIC SPINES; DIHYDROXYPHENYLALANINE; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; FOOD; HIPPOCAMPUS; INFLAMMATION; MEMORY; MICE, TRANSGENIC; NERVE DEGENERATION; NEURONAL PLASTICITY; NUCLEUS ACCUMBENS; PLAQUE, AMYLOID; REWARD; SELEGILINE; VENTRAL TEGMENTAL AREA;

EID: 85016723934     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms14727     Document Type: Article

References (70)

1. Nelson, P. T. et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: A review of the literature. J. Neuropathol. Exp. Neurol. 71, 362-381 (2012).
2. Scheltens, P. et al. Alzheimer's disease. Lancet 388, 505-517 (2016).
3. D'Amelio, M. & Rossini, P. M. Brain excitability and connectivity of neuronal assemblies in Alzheimer's disease: from animal models to human findings. Prog. Neurobiol. 99, 42-60 (2012).
4. Roy, D. S. et al. Memory retrieval by activating engram cells in mouse models of early Alzheimer's disease. Nature 531, 508-512 (2016).
5. Scheff, S. W., Price, D. A., Schmitt, F. A. & Mufson, E. J. Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiol. Aging 27, 1372-1384 (2006).
6. Wang, S.-H. & Morris, R. G. M. Hippocampal-neocortical interactions in memory formation, consolidation, and reconsolidation. Annu. Rev. Psychol. 61, 49-79, C1-C4 (2010).
7. Segal, M., Markram, H. & Richter-Levin, G. Actions of norepinephrine in the rat hippocampus. Prog. Brain Res. 88, 323-330 (1991).
8. Schmitz, D., Gloveli, T., Empson, R. M. & Heinemann, U. Comparison of the effects of serotonin in the hippocampus and the entorhinal cortex. Mol. Neurobiol. 17, 59-72 (1998).
9. Drever, J., Straube, A. & Eggert, T. Learning deferred imitation of long spatial sequences. Behav. Brain Res. 220, 74-82 (2011).
10. Mather, M. & Harley, C. W. The locus coeruleus: essential for maintaining cognitive function and the aging brain. Trends Cogn. Sci. 20, 214-226 (2016).
11. Trillo, L. et al. Ascending monoaminergic systems alterations in Alzheimer's disease.Translating basic science into clinical care. Neurosci. Biobehav. Rev. 37, 1363-1379 (2013).
12. Van Hoesen, G. W. & Hyman, B. T. Hippocampal formation: Anatomy and the patterns of pathology in Alzheimer's disease. Prog. Brain Res. 83, 445-457 (1990).
13. Hyman, B. T., Van Hoesen, G. W., Damasio, A. R. & Barnes, C. L. Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science 225, 1168-1170 (1984).
14. Burns, J. M., Galvin, J. E., Roe, C. M., Morris, J. C. & McKeel, D. W. The pathology of the substantia nigra in Alzheimer disease with extrapyramidal signs. Neurology 64, 1397-1403 (2005).
15. Gibb, W. R., Mountjoy, C. Q., Mann, D. M. & Lees, A. J. The substantia nigra and ventral tegmental area in Alzheimer's disease and Down's syndrome. J. Neurol. Neurosurg. Psychiatry 52, 193-200 (1989).
16. Storga, D., Vrecko, K., Birkmayer, J. G. & Reibnegger, G. Monoaminergic neurotransmitters, their precursors and metabolites in brains of Alzheimer patients. Neurosci. Lett. 203, 29-32 (1996).
17. Russo, S. J. & Nestler, E. J. The brain reward circuitry in mood disorders. Nat. Rev. Neurosci. 14, 609-625 (2013).
18. Rossato, J. I., Bevilaqua, L. R. M., Izquierdo, I., Medina, J. H. & Cammarota, M. Dopamine controls persistence of long-Term memory storage. Science 325, 1017-1020 (2009).
19. McNamara, C. G., Tejero-Cantero, A., Trouche, S., Campo-Urriza, N. & Dupret, D. Dopaminergic neurons promote hippocampal reactivation and spatial memory persistence. Nat. Neurosci. 17, 1658-1660 (2014).
20. Broussard, J. I. et al. Dopamine regulates aversive contextual learning and associated in vivo synaptic plasticity in the hippocampus. Cell Rep. 14, 1930-1939 (2016).
21. Hsiao, K. et al. Correlative memory deficits, Ab elevation, and amyloid plaques in transgenic mice. Science 274, 99-102 (1996).
22. Jung, J. H., An, K., Kwon, O. B., Kim, H. & Kim, J.-H. Pathway-specific alteration of synaptic plasticity in Tg2576 mice. Mol. Cells 32, 197-201 (2011).
23. Jacobsen, J. S. et al. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. USA 103, 5161-5166 (2006).
24. Chapman, P. F. et al. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat. Neurosci. 2, 271-276 (1999).
25. D'Amelio, M. et al. Caspase-3 triggers early synaptic dysfunction in a mouse model of Alzheimer's disease. Nat. Neurosci. 14, 69-76 (2011).
26. Masters, M. C., Morris, J. C. & Roe, C. M. 'Noncognitive' symptoms of early Alzheimer disease: A longitudinal analysis. Neurology 84, 617-622 (2015).
27. Middeldorp, J. & Hol, E. M. GFAP in health and disease. Prog. Neurobiol. 93, 421-443 (2011).
28. Ito, D. et al. Microglia-specific localisation of a novel calcium binding protein, Iba1. Brain Res. Mol. Brain Res. 57, 1-9 (1998).
29. Nimmerjahn, A., Kirchhoff, F. & Helmchen, F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308, 1314-1318 (2005).
30. Davalos, D. et al. ATP mediates rapid microglial response to local brain injury in vivo. Nat. Neurosci. 8, 752-758 (2005).
31. Lisman, J. E. & Grace, A. A. The hippocampal-VTA loop: controlling the entry of information into long-Term memory. Neuron 46, 703-713 (2005).
32. Calabresi, P., Picconi, B., Tozzi, A., Ghiglieri, V. & Di Filippo, M. Direct and indirect pathways of basal ganglia: A critical reappraisal. Nat. Neurosci. 17, 1022-1030 (2014).
33. Gerfen, C. R., Herkenham, M. & Thibault, J. The neostriatal mosaic: II. Patch-And matrix-directed mesostriatal dopaminergic and non-dopaminergic systems. J. Neurosci. 7, 3915-3934 (1987).
34. Lammel, S. et al. Unique properties of mesoprefrontal neurons within a dual mesocorticolimbic dopamine system. Neuron 57, 760-773 (2008).
35. Chuhma, N., Mingote, S., Kalmbach, A., Yetnikoff, L. & Rayport, S. Heterogeneity in dopamine neuron synaptic actions across the striatum and its relevance for schizophrenia. Biol. Psychiatry 81, 43-51 (2017).
36. Rice, M. E., Patel, J. C. & Cragg, S. J. Dopamine release in the basal ganglia. Neuroscience 198, 112-137 (2011).
37. Kosillo, P., Zhang, Y.-F., Threlfell, S. & Cragg, S. J. Cortical control of striatal dopamine transmission via striatal cholinergic interneurons. Cereb. Cortex 26, 4160-4169 (2016).
38. Ito, R. & Hayen, A. Opposing roles of nucleus accumbens core and shell dopamine in the modulation of limbic information processing. J. Neurosci. 31, 6001-6007 (2011).
39. Rosen, Z. B., Cheung, S. & Siegelbaum, S. A. Midbrain dopamine neurons bidirectionally regulate CA3-CA1 synaptic drive. Nat. Neurosci. 18, 1763-1771 (2015).
40. Devoto, P, Flore, G. on the Origin of Cortical Dopamine: Is It A Co-Transmitter in Noradrenergic Neurons? Curr. Neuropharmacol. 4, 115-125 (2006).
41. Smith, C. C. & Greene, R. W. CNS dopamine transmission mediated by noradrenergic innervation. J. Neurosci. 32, 6072-6080 (2012).
42. Takeuchi, T. et al. Locus coeruleus and dopaminergic consolidation of everyday memory. Nature 537, 357-362 (2016).
43. Guérin, D., Sacquet, J., Mandairon, N., Jourdan, F. & Didier, A. Early locus coeruleus degeneration and olfactory dysfunctions in Tg2576 mice. Neurobiol. Aging 30, 272-283 (2009).
44. Liu, Y. et al. Amyloid pathology is associated with progressive monoaminergic neurodegeneration in a transgenic mouse model of Alzheimer's disease. J. Neurosci. 28, 13805-13814 (2008).
45. Koch, G. et al. Altered dopamine modulation of LTD-like plasticity in Alzheimer's disease patients. Clin. Neurophysiol. 122, 703-707 (2011).
46. Koch, G. et al. Dopaminergic modulation of cortical plasticity in Alzheimer's disease patients. Neuropsychopharmacology 39, 2654-2661 (2014).
47. Monteverde, A., Gnemmi, P., Rossi, F., Monteverde, A. & Finali, G. C. Selegiline in the treatment of mild to moderate Alzheimer-Type dementia. Clin. Ther. 12, 315-322 (1990).
48. Martorana, A. & Koch, G. Is dopamine involved in Alzheimer's disease? Front. Aging Neurosci. 6, 252 (2014).
49. Guzmán-Ramos, K. et al. Restoration of dopamine release deficits during object recognition memory acquisition attenuates cognitive impairment in a triple transgenic mice model of Alzheimer's disease. Learn. Mem. 19, 453-460 (2012).
50. Himeno, E. et al. Apomorphine treatment in Alzheimer mice promoting amyloid-b degradation. Ann. Neurol. 69, 248-256 (2011).
51. Jürgensen, S. et al. Activation of D1/D5 dopamine receptors protects neurons from synapse dysfunction induced by amyloid-beta oligomers. J. Biol. Chem. 286, 3270-3276 (2011).
52. Tsunekawa, H., Noda, Y., Mouri, A., Yoneda, F. & Nabeshima, T. Synergistic effects of selegiline and donepezil on cognitive impairment induced by amyloid beta (25-35). Behav. Brain Res. 190, 224-232 (2008).
53. Pazini, A. M. et al. Selegiline reverses Ab25-35-induced cognitive deficit in male mice. Neurochem. Res. 38, 2287-2294 (2013).
54. Mercuri, N. B., Scarponi, M., Bonci, A., Siniscalchi, A. & Bernardi, G. Monoamine oxidase inhibition causes a long-Term prolongation of the dopamine-induced responses in rat midbrain dopaminergic cells. J. Neurosci. 17, 2267-2272 (1997).
55. Gao, C., Sun, X. & Wolf, M. E. Activation of D1 dopamine receptors increases surface expression of AMPA receptors and facilitates their synaptic incorporation in cultured hippocampal neurons. J. Neurochem. 98, 1664-1677 (2006).
56. Hao, J.-R. et al. L-Stepholidine rescues memory deficit and synaptic plasticity in models of Alzheimer's disease via activating dopamine D1 receptor/PKA signaling pathway. Cell Death Dis. 6, e1965 (2015).
57. Ambrée, O. et al. Levodopa ameliorates learning and memory deficits in a murine model of Alzheimer's disease. Neurobiol. Aging 30, 1192-1204 (2009).
58. Yuan Xiang, P., Janc, O., Grochowska, K. M., Kreutz, M. R. & Reymann, K. G. Dopamine agonists rescue Ab-induced LTP impairment by Src-family tyrosine kinases. Neurobiol. Aging 40, 98-102 (2016).
59. Moreno-Castilla, P. et al. Dopaminergic neurotransmission dysfunction induced by amyloid-b transforms cortical long-Term potentiation into long-Term depression and produces memory impairment. Neurobiol. Aging 41, 187-199 (2016).
60. Joyce, J. N., Kaeger, C., Ryoo, H. & Goldsmith, S. Dopamine D2 receptors in the hippocampus and amygdala in Alzheimer's disease. Neurosci. Lett. 154, 171-174 (1993).
61. Tanaka, Y. et al. Decreased striatal D2 receptor density associated with severe behavioral abnormality in Alzheimer's disease. Ann. Nucl. Med. 17, 567-573 (2003).
62. Ford, C. P., Mark, G. P. & Williams, J. T. Properties and opioid inhibition of mesolimbic dopamine neurons vary according to target location. J. Neurosci. 26, 2788-2797 (2006).
63. Krashia, P. et al. On the properties of identified dopaminergic neurons in the mouse substantia nigra and ventral tegmental area. Eur. J. Neurosci. 45, 92-105 (2016).
64. Wilcock, G. K., Birks, J., Whitehead, A. & Evans, S. J. G. The effect of selegiline in the treatment of people with Alzheimer's disease: A meta-Analysis of published trials. Int. J. Geriatr. Psychiatry 17, 175-183 (2002).
65. Burke, R. E. & O'Malley, K. Axon degeneration in Parkinson's disease. Exp. Neurol. 246, 72-83 (2013).
66. Marcyniuk, B., Mann, D. M. & Yates, P. O. The topography of cell loss from locus coeruleus in Alzheimer's disease. J. Neurol. Sci. 76, 335-345 (1986).
67. German, D. C. et al. Disease-specific patterns of locus coeruleus cell loss. Ann. Neurol. 32, 667-676 (1992).
68. Parvizi, J., Van Hoesen, G. W. & Damasio, A. The selective vulnerability of brainstem nuclei to Alzheimer's disease. Ann. Neurol. 49, 53-66 (2001).
69. Chan, C. S., Gertler, T. S. & Surmeier, D. J. A molecular basis for the increased vulnerability of substantia nigra dopamine neurons in aging and Parkinson's disease. Mov. Disord. 25, S63-S70 (2010).
70. Paxinos, G. & Franklin, K. The Mouse Brain in Stereotaxic Coordinates 4th edn (Elsevier/Academic Press, 2012).